ğŸ§¬ GENE OF THE WEEK: DPYD

A potentially fatal pharmacogenomic interaction. DPYD deficiency can cause severe, life-threatening toxicity from common chemotherapy drugs.

âš ï¸ CRITICAL WARNING:

3-5% of population has partial DPYD deficiency
0.1% have complete deficiency

Standard doses of 5-FU or capecitabine can cause DEATH in deficient patients.

European guidelines now REQUIRE DPYD testing before fluoropyrimidine therapy.

DPYD Activity Levels:

Normal Metabolizer:
âœ… Full enzyme activity
âœ… Standard dosing OK
âœ… Normal toxicity risk

Intermediate (3-5%):
âš ï¸ 25-50% dose reduction needed
âš ï¸ Increased toxicity risk
âš ï¸ Severe mucositis, diarrhea possible

Poor Metabolizer (0.1%):
ğŸš« AVOID fluoropyrimidines
ğŸš« Life-threatening toxicity
ğŸš« Neutropenia, sepsis, death risk

Affected Drugs:

ğŸ’Š 5-Fluorouracil (5-FU)
ğŸ’Š Capecitabine (Xeloda)
ğŸ’Š Tegafur

Used for colorectal, breast, head/neck cancers.

Test BEFORE prescribing. This is actionable pharmacogenomics.

ğŸ‘¨â€âš•ï¸ Physicians: Why aren't you using Bioscope.AI to offer true AI-powered precision medicine?

ğŸ§‘ Patients: Why isn't your physician using Bioscope.AI to maximize your healthy longevity?

#GeneOfTheWeek #DPYD #Chemotherapy #Pharmacogenomics #Bioscope
